1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Warfarin |
| brand | String | Coumadin (discontinued in US but name in common use), Jantoven |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Anticoagulants|Anticoagulant]] • [[:Category:Vitamin_K_antagonists|Vitamin K antagonist]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' |
| starting_dose | String | Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice |
| preparations | String | 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets (color-coded by strength) |
| fda_max | String | No fixed maximum; titrated to INR target |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • IV (rarely used; same dose) |
| onset | String | Anticoagulant effect at 24-72 hours; full INR effect 5-7 days |
| duration | String | 2-5 days after stopping (factor II resynthesis-limited) |
| halflife | String | 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)'"`UNIQ--ref-00000020-QINU`"' |
| bioavailability | String | ~100% (oral)'"`UNIQ--ref-00000021-QINU`"' |
| pregnancy | String | '''Contraindicated in pregnancy''' (warfarin embryopathy, fetal hemorrhage) except in mechanical mitral valves where the maternal mortality of alternative agents may exceed fetal risk.'"`UNIQ--ref-00000022-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
